Premium
Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies
Author(s) -
Oda Katsutoshi,
Ikeda Yuji,
Kashiyama Tomoko,
Miyasaka Aki,
Inaba Kanako,
Fukuda Tomohiko,
Asada Kayo,
Sone Kenbun,
WadaHiraike Osamu,
Kawana Kei,
Osuga Yutaka,
Fujii Tomoyuki
Publication year - 2016
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.13018
Subject(s) - pi3k/akt/mtor pathway , medicine , kinase , cancer research , palbociclib , everolimus , olaparib , signal transduction , autophagy , cancer , pharmacology , biology , microbiology and biotechnology , oncology , polymerase , poly adp ribose polymerase , genetics , gene , breast cancer , metastatic breast cancer , apoptosis
Recent developments in genomic analysis have unveiled the key signaling pathways in human cancer. However, only a limited number of molecular‐targeted drugs are applicable for clinical use in gynecologic malignancies. TP53 signaling and phosphatidylinositol 3 kinase pathways are frequently mutated in cancer, and have received much attention as molecular targets in human cancers. In this review, we mainly focus on the functions of these pathways, and discuss the molecular‐targeted drugs under clinical trials. The molecular‐targeted drugs described in this review include dual phosphatidylinositol 3 kinase/mTOR inhibitors (NVP‐BEZ235, DS‐7423, SAR245409), an mTOR inhibitor (everolimus), an MEK inhibitor (pimasertib), an autophagy inhibitor (chloroquine), a cyclin‐dependent kinases 4/6 inhibitor (PD0332991), and a poly (ADP‐ribose) polymerase inhibitor (olaparib).